Equities research analysts expect Qiagen NV (NYSE:QGEN) to announce earnings of $0.26 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Qiagen’s earnings. The highest EPS estimate is $0.27 and the lowest is $0.25. Qiagen also reported earnings of $0.26 per share during the same quarter last year. The business is expected to announce its next quarterly earnings report on Wednesday, May 1st.
According to Zacks, analysts expect that Qiagen will report full-year earnings of $1.45 per share for the current year, with EPS estimates ranging from $1.43 to $1.47. For the next financial year, analysts forecast that the firm will post earnings of $1.64 per share, with EPS estimates ranging from $1.60 to $1.65. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Qiagen.
Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, February 4th. The company reported $0.40 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.40. Qiagen had a net margin of 12.68% and a return on equity of 12.15%. The firm had revenue of $403.20 million for the quarter, compared to the consensus estimate of $409.32 million. During the same period in the previous year, the company earned $0.43 earnings per share. The company’s quarterly revenue was up 1.6% on a year-over-year basis.
Several institutional investors and hedge funds have recently added to or reduced their stakes in QGEN. Sycomore Asset Management purchased a new position in shares of Qiagen during the fourth quarter worth $86,182,000. American Century Companies Inc. raised its stake in shares of Qiagen by 111.7% in the fourth quarter. American Century Companies Inc. now owns 995,508 shares of the company’s stock valued at $34,295,000 after acquiring an additional 525,268 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Qiagen by 4.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 12,615,185 shares of the company’s stock valued at $434,593,000 after acquiring an additional 481,606 shares in the last quarter. Millennium Management LLC raised its stake in shares of Qiagen by 172.7% in the fourth quarter. Millennium Management LLC now owns 650,831 shares of the company’s stock valued at $22,421,000 after acquiring an additional 412,211 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Qiagen by 116.5% in the fourth quarter. Jane Street Group LLC now owns 685,032 shares of the company’s stock valued at $23,599,000 after acquiring an additional 368,567 shares in the last quarter. Institutional investors and hedge funds own 64.77% of the company’s stock.
Shares of Qiagen stock opened at $39.92 on Friday. The stock has a market cap of $9.09 billion, a price-to-earnings ratio of 30.10, a PEG ratio of 2.49 and a beta of 0.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.22. Qiagen has a 12-month low of $31.10 and a 12-month high of $40.42.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Recommended Story: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.